

**Moxifloxacin Solid Formulation**

Version 3.2      Revision Date: 09/13/2019      SDS Number: 1731674-00006      Date of last issue: 04/24/2019  
Date of first issue: 06/05/2017

---

**SECTION 1. IDENTIFICATION**

Product name : Moxifloxacin Solid Formulation

**Manufacturer or supplier's details**

Company name of supplier : Merck & Co., Inc  
Address : 2000 Galloping Hill Road  
Kenilworth - New Jersey - U.S.A. 07033  
Telephone : 908-740-4000  
Telefax : 908-735-1496  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with 29 CFR 1910.1200**

Acute toxicity (Oral) : Category 4  
Eye irritation : Category 2B  
Reproductive toxicity : Category 2  
Specific target organ toxicity : Category 2 (Liver)  
- repeated exposure

**GHS label elements**

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.  
H320 Causes eye irritation.  
H361d Suspected of damaging the unborn child.  
H373 May cause damage to organs (Liver) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

## Moxifloxacin Solid Formulation

Version 3.2      Revision Date: 09/13/2019      SDS Number: 1731674-00006      Date of last issue: 04/24/2019  
 Date of first issue: 06/05/2017

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.  
 P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
 P308 + P313 IF exposed or concerned: Get medical advice/attention.  
 P337 + P313 If eye irritation persists: Get medical advice/attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

None known.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	>= 40 - <= 70
Cellulose	9004-34-6	>= 10 - <= 30

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
 Remove contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
 If easy to do, remove contact lens, if worn.  
 Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention.  
 Rinse mouth thoroughly with water.  
 Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and : Harmful if swallowed.  
 Causes eye irritation.

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731674-00006	Date of first issue: 06/05/2017

delayed : Suspected of damaging the unborn child.  
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

**Moxifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731674-00006	Date of first issue: 06/05/2017

- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not swallow.  
Do not get in eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m <sup>3</sup> (OEB 2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable)	5 mg/m <sup>3</sup>	NIOSH REL
		TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
		TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
		TWA (respirable fraction)	5 mg/m <sup>3</sup>	OSHA Z-1

- Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
- Hand protection  
Material : Chemical-resistant gloves

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731674-00006	Date of first issue: 06/05/2017

---

Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	solid
Color	:	pink
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available

**Moxifloxacin Solid Formulation**

Version 3.2      Revision Date: 09/13/2019      SDS Number: 1731674-00006      Date of last issue: 04/24/2019  
Date of first issue: 06/05/2017

---

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : Not applicable

Particle size : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Harmful if swallowed.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 1,886 mg/kg  
Method: Calculation method

**Components:****Moxifloxacin HCL:**

Acute oral toxicity : LD50 (Rat): 1,320 mg/kg

---

**Moxifloxacin Solid Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.2                09/13/2019              1731674-00006        Date of first issue: 06/05/2017

---

LD50 (Mouse): > 435 mg/kg

LD50 (Monkey): 1,500 mg/kg

**Cellulose:**

Acute oral toxicity            : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity    : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity        : LD50 (Rabbit): > 2,000 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Moxifloxacin HCL:**

Species                        : Rabbit  
Result                         : No skin irritation

**Serious eye damage/eye irritation**

Causes eye irritation.

**Components:****Moxifloxacin HCL:**

Species                        : Rabbit  
Result                         : Moderate eye irritation

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Moxifloxacin HCL:**

Genotoxicity in vitro        : Test Type: Bacterial reverse mutation assay (AMES)  
Result: positive

Test Type: Chromosome aberration test in vitro  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731674-00006	Date of first issue: 06/05/2017

---

Test Type: in vitro micronucleus test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Application Route: Oral  
Result: negative

### Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Cellulose:

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity

Suspected of damaging the unborn child.

### Components:

#### Moxifloxacin HCL:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: LOAEL: 500 mg/kg body weight  
Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development



## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731674-00006	Date of first issue: 06/05/2017

---

Species: Monkey  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 10 mg/kg body weight  
 Result: negative

Test Type: Embryo-fetal development  
 Species: Rabbit  
 Application Route: Intravenous injection  
 Developmental Toxicity: LOAEL: 20 mg/kg body weight  
 Symptoms: Skeletal malformations.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

May cause damage to organs (Liver) through prolonged or repeated exposure.

### Components:

#### Moxifloxacin HCL:

Target Organs : Liver  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

#### Moxifloxacin HCL:

Species : Rat  
 LOAEL : 100 mg/kg  
 Application Route : Oral  
 Exposure time : 4 Weeks

Species : Rat  
 NOAEL : 100 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Liver  
 Symptoms : Liver disorders

**Moxifloxacin Solid Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.2                09/13/2019              1731674-00006        Date of first issue: 06/05/2017

---

Species                : Rat  
NOAEL                 : 20 mg/kg  
Application Route     : Oral  
Exposure time        : 6 Months  
Target Organs         : Liver  
Symptoms              : Liver disorders

Species                : Monkey  
NOAEL                 : 50 mg/kg  
Application Route     : Oral  
Exposure time        : 4 Weeks  
Symptoms              : No adverse effects.

Species                : Monkey  
NOAEL                 : 15 mg/kg  
Application Route     : Oral  
Exposure time        : 13 Weeks  
Target Organs         : Gastrointestinal tract  
Symptoms              : Vomiting

Species                : Monkey  
Application Route     : Oral  
Exposure time        : 26 Weeks  
Target Organs         : Liver  
Symptoms              : Liver disorders

**Cellulose:**

Species                : Rat  
NOAEL                 :  $\geq 9,000$  mg/kg  
Application Route     : Ingestion  
Exposure time        : 90 Days

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Moxifloxacin HCL:**

Ingestion              : Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish            : LC50 (Oryzias latipes (Japanese medaka)):  $> 100$  mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

---

**Moxifloxacin Solid Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.2                09/13/2019                1731674-00006            Date of first issue: 06/05/2017

---

**Persistence and degradability****Components:****Cellulose:**

Biodegradability                                :    Result: Readily biodegradable.

**Bioaccumulative potential**

No data available

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues                                :    Dispose of in accordance with local regulations.  
Contaminated packaging                                :    Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

---

**SECTION 15. REGULATORY INFORMATION****EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

---

## Moxifloxacin Solid Formulation

Version 3.2      Revision Date: 09/13/2019      SDS Number: 1731674-00006      Date of last issue: 04/24/2019  
 Date of first issue: 06/05/2017

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Acute toxicity (any route of exposure)  
 Serious eye damage or eye irritation  
 Reproductive toxicity  
 Specific target organ toxicity (single or repeated exposure)

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### US State Regulations

#### Pennsylvania Right To Know

Moxifloxacin HCL 186826-86-8  
 Cellulose 9004-34-6

#### California Permissible Exposure Limits for Chemical Contaminants

Cellulose 9004-34-6


#### The ingredients of this product are reported in the following inventories:

AICS : not determined  
 DSL : not determined  
 IECSC : not determined

## SECTION 16. OTHER INFORMATION

### Further information

#### NFPA 704:



#### HMIS® IV:

<b>HEALTH</b>	*	2
<b>FLAMMABILITY</b>	1	
<b>PHYSICAL HAZARD</b>	0	

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 NIOSH REL : USA. NIOSH Recommended Exposure Limits

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731674-00006	Date of first issue: 06/05/2017

OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <a href="http://echa.europa.eu/">http://echa.europa.eu/</a>
--	---	---

Revision Date	:	09/13/2019
---------------	---	------------

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific

# SAFETY DATA SHEET



## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.2	09/13/2019	1731674-00006	Date of first issue: 06/05/2017

---

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8